All Blogs

Aug 02, 2018

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple my...

Aug 01, 2018

‘Reprogrammed’ stem cells to be tested in people with Parkinson’s Doctors in Japan are poised to implant neural cells made from ‘reprogrammed’ stem cells into the brains of people with Parkinson’s disease. It is only the third clinical application of induced pluripotent stem (iPS) cells, which are developed by repro...

Jul 27, 2018

Niemann-Pick disease type C (NPC) is a lipid storage disease that can present in infants, children, or adults. Neonates can present with ascites and severe liver disease from infiltration of the liver and/or respiratory failure from infiltration of the lungs. The classic presentation occurs in mid-to-late childhood ...

Jul 25, 2018

The FDA has approved AbbVie's Gonadotropin-Releasing Hormone (GnRH) antagonist Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per...

Jul 20, 2018

Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from solid tumours, metastases of ALL seldom involve the parenchyma but are isolated to the leptomeninges, which is an infrequent site for carcinomatous invasion. Although metastasis to the CNS occur...

Jul 19, 2018

Sanofi bags rights to Revolution’s SHP2 cancer drug Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drugs against SHP2. The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year. Sanofi has also committed to covering the R&D costs ...

Jul 17, 2018

Novartis to Spin-Off Eye Care Device Business Swiss pharmaceutical major, Novartis, has announced it plan to spin-off Alcon, its eye care division, into a separately-traded standalone company. The company has sought shareholder approval for 100% spinoff of Alcon, its eye care device business and also ini...

Jul 17, 2018

AbbVie’s Orilissa for Endometriosis Pain Management Receives FDA Approval AbbVie in cooperation with Neurocrine Biosciences announced that the U.S. FDA approved Orilissa (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe e...

Jul 17, 2018

Alkermes Gets FDA approval for Aristada Initio (aripiprazole lauroxil) as Part of  Schizophrenia Treatment Combination  Alkermes has announced that the U.S. FDA approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic f...

Jul 17, 2018

Keytruda, the First Anti-PD-1 Therapy for Advanced Melanoma, Approved in China Merck announced that Keytruda, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior lin...